cCAM Biotherapeutics Announced Today the Completion of its Series A Financing
TEL HAI, Israel, September 14, 2012 /PRNewswire/ --
cCAM Biotherapeutics, a biopharmaceutical company focused on the discovery and development of novel immunomodulatory drugs for cancer, announced today the completion of its Series A financing . The round was led by Arkin Holdings and included participation from OrbiMed's Israel Partners, Pontifax and F.Hoffmann La Roche. ROG.VX.
cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory humanized monoclonal antibody that harnesses the patient's immune system to attack tumors. CM-10 targets CEACAM1, a receptor newly characterized as an immune checkpoint used by cancer cells to suppress the immune system. Upon binding to CEACAM1, CM-10 leads to a cancer specific immune response.
"We are very pleased to expand our circle of industry-leading investors," said Dr. Tehila Ben Moshe, cCAM Bio's CEO. "With our series A complete, we are in a position to advance our lead antibody through a proof of concept study in humans."
Visit: http://www.ccam-bio.com
Contact details:
Tehila Ben-Moshe, Ph.D
CEO
cCAM Biotherapeutics Ltd.
Tel: +1(972)-4-9534651, +1(972)-52-3319649
email: tehila@ccam-bio.com
SOURCE cCAM Biotherapeutics Ltd
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos and customised feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Start today.